Drug Trial Radar · NCT05456932
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
Last checked: Nov 20, 2026Latest source record: Mar 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 19, 2022
Primary completion
Aug 31, 2023
Study completion Aug 31, 2023
Sponsor
- Lead sponsor
- Leiden University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University Medical Center Groningen; Radboud University Medical Center; Maastricht University Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Iron deficiency anemia is the most common systemic manifestation of Inflammatory Bowel Diseases (IBD)-Crohn's disease and ulcerative colitis. Iron deficiency with or without anemia poses a diagnostic and therapeutic challenge due to chronic gastrointestinal blood loss and the inflammatory nature of IBD. Recent illumination of iron metabolism has brought attention to the systemic iron regulator-hepcidin, a peptide hormone that regulates intestinal iron absorption and systemic iron availability. Elevated hepcidin is associated with oral iron malabsorption in IBD. This study aims to evaluate whether hepcidin concentration at baseline can predict response to oral and intravenous iron therapy in patients with IBD and concomitant iron deficiency with or without anemia.
Conditions
- Inflammatory Bowel Diseases
- Iron-deficiency
- Iron Deficiency Anemia
Interventions
Intravenous ironDrug
Included participants will receive intravenous iron therapy, the dosage will be based on national pharmaceutical formulary.
Ferric maltolDrug
Included participants will receive oral iron therapy with ferric maltol (twice a day 30mg for 12 weeks)
Ferrous fumarateDrug
Included participants will receive oral iron therapy with ferrous fumarate (twice a day 100mg for 12 weeks)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The discriminative capacity of hepcidin at baseline to differentiate between response and non-response to iron therapy with oral ferrous fumarateTime frame: Week 14
- The discriminative capacity of hepcidin at baseline to differentiate between response and non-response to iron therapy with oral ferric maltolTime frame: Week 14
- The discriminative capacity of hepcidin at baseline to differentiate between response and non-response to intravenous iron therapyTime frame: Week 14
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Amsterdam University Medical Center
Amsterdam, Netherlands · Recruiting
University Medical Center Groningen
Groningen, Netherlands · Recruiting
Leiden University Medical Center (LUMC)
Leiden, Netherlands · Recruiting
Maastricht University Medical Center+
Maastricht, Netherlands · Recruiting
Radboud University Medical Center
Nijmegen, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.